Study of SHR-A1811 for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer that can be seen on scans.
- You are able to do your daily activities with little or no help.
- Your doctor expects you to live at least 12 more weeks.
- You do not have untreated or active brain metastases.
- You do not have uncontrolled heart disease.
- You do not have active hepatitis B or C.
- You do not have a serious active infection like tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests an investigational medicine called SHR-A1811 for ovarian cancer that has come back after platinum-based chemotherapy. It targets a protein called HER2 on cancer cells to try to stop their growth. This trial is for people who have already tried a PARP inhibitor and have certain genetic features.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This study tests an experimental drug called SHR-A1811 given as a shot under the skin (subcutaneous injection) for people with solid tumors. It aims to see if the drug is safe and how well it works.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.